Lunai Bioworks
Tracked across 1 events · 6 articles · First seen Sep 22, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Lunai Bioworks announced an exclusive worldwide license and collaboration agreement with Tanaist to add human cellular phenotyping to its Parkinson's disease discovery and validation platform. Under the deal, Lunai gains exclusive rights to Tanaist's licensed…
Impact: Lunai Bioworks is the central party, securing exclusive worldwide rights to Tanaist's cellular phenotyping technology to validate its AI-driven Parkinson's subtypes. The deal expands its discovery platform and could enhance its attractiveness to pharmaceutical partners, though near-term financial impact is limited.
Sep 22, 2026 · 6 articles
70
Lunai Bioworks signed license agreement TanaistLunai Tanaist Parkinson...
30
Lunai Bioworks collaborated with United Therapeutics United TherapeuticsLunai Tanaist Parkinson...
ERGEN INTELLIGENCE
Track Lunai Bioworks live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard